Linda J Zhu, MD
Allergy/Immunology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · Lpch Medical Group Div of Lucile
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Zhu’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A161744 · Current
Licensed to practise in California · since 2019 · expires 2027-04-30 · Case Western Reserve University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$30,203
Medicare paid this office $30,203 for 107 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 31 | $6,389 | $206 |
| Long return visit (40+ min) | 29 | $5,984 | $171 |
| Return visit (30+ min) | 25 | $3,194 | $103 |
| New patient visit (45+ min) | 20 | $3,033 | $152 |
| Short return visit (20+ min) | 31 | $2,637 | $82 |
See all 8 services
| New patient visit (60+ min) | 31 | $6,389 | $206 |
| Long return visit (40+ min) | 29 | $5,984 | $171 |
| Return visit (30+ min) | 25 | $3,194 | $103 |
| New patient visit (45+ min) | 20 | $3,033 | $152 |
| Short return visit (20+ min) | 31 | $2,637 | $82 |
| Test for allergy using combination of methods with drug or biological | 12 | $2,488 | $21 |
| Test for allergy using ingested items, initial 2 hours | 11 | $1,349 | $123 |
| Short return visit | 12 | $665 | $55 |
Who their Medicare patients are
107 Original Medicare patients in 2024. Average age 71 · Women 65% · Also on Medicaid 18% · Health risk score 2.00. Sicker patients than 9 in 10 peers; the typical allergy/ immunology clinician is at 1.
Conditions among them: High blood pressure 63% · Depression 29% · Diabetes 27% · Coronary heart disease 26% · Chronic kidney disease 24% · Cancer 23% · COPD 21% · Atrial fibrillation 20% · Heart failure 18%.
The office billed $139,760, Medicare allowed $38,750 and paid $30,203; for 986 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 107 | 986 | 71 | 2.00 | $139,760 | $30,203 |
| 2023 | 99 | 1,165 | 71 | 1.52 | $157,308 | $30,799 |
| 2022 | 56 | 382 | 68 | 1.57 | $84,559 | $16,965 |
| 2021 | 35 | 383 | 67 | 1.60 | $61,989 | $11,878 |
| 2018 | 18 | 26 | 76 | 2.00 | $8,176 | $1,033 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| New patient visit (60+ min) | 45 | $8,726 | $194 |
| Long return visit (40+ min) | 15 | $3,936 | $171 |
| Test for allergy using combination of methods with drug or biological | 16 | $3,011 | $21 |
| Test for allergy using allergenic extract | 15 | $2,875 | $4 |
| Return visit (30+ min) | 23 | $2,634 | $101 |
| New patient visit (45+ min) | 17 | $2,345 | $138 |
| Telehealth originating site facility fee | 77 | $2,200 | $21 |
| Test for allergy using ingested items, initial 2 hours | 13 | $1,816 | $121 |
| Short return visit (20+ min) | 21 | $1,746 | $83 |
2022: 4 services
| New patient visit (60+ min) | 21 | $4,296 | $205 |
| Long return visit (40+ min) | 15 | $3,576 | $163 |
| New patient visit (45+ min) | 11 | $1,559 | $142 |
| Telehealth originating site facility fee | 42 | $1,352 | $21 |
2021: 2 services
| New patient visit (60+ min) | 21 | $4,443 | $212 |
| Telehealth originating site facility fee | 30 | $859 | $22 |
2018: 1 service
| Insertion of artery tube for blood sampling or infusion through skin | 14 | $498 | $36 |
Medicaid work
$2,190 in 2023
Medicaid paid $2,190 for 71 billed services this clinician did in 2023, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Telehealth originating site facility fee | 71 | $2,190 |
| 2023 | 71 | 1 | 14 | $2,190 |
| 2022 | 36 | 1 | 12 | $1,100 |
| 2021 | 64 | 1 | 21 | $1,991 |
See the largest Medicaid services in earlier years
2022
| Telehealth originating site facility fee | 36 | $1,100 |
2021
| Telehealth originating site facility fee | 64 | $1,991 |
Drugs they prescribed that Part D paid
$107,288
Pharmacies billed $107,288 in 2024. Most of that is one immune-globulin drugs at about $7,000 a fill for a small number of people.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 124) in 2024. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 0%.
92 generic and 32 brand-name prescriptions · $107,288 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hizentra | Immune globulin | 13 | $95,893 | $7,376 |
| Epinephrine | None | 12 | $2,023 | $169 |
| Azelastine | None | 20 | $705 | $35 |
| Ipratropium | None | 18 | $616 | $34 |
| Fluticasone Propionate | None | 25 | $304 | $12 |
Year by year
| 2024 | 124 | 43 | 0% (0) | 26% | $107,288 |
| 2023 | 122 | 39 | 0% (0) | 31% | $125,320 |
| 2022 | 71 | 20 | 0% (0) | 23% | $42,160 |
| 2021 | 51 | 20 | 0% (0) | 31% | $14,211 |
| 2017 | 228 | 27 | None | None | $12,480 |
| 2016 | 299 | 36 | 7% (22) | None | $7,473 |
| 2015 | 78 | 27 | None | None | $2,602 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Hizentra | Immune globulin | 13 | $110,448 | $8,496 |
| Epinephrine | None | 15 | $4,164 | $278 |
| Azelastine | None | 33 | $1,962 | $59 |
| Fluticasone Propionate | None | 16 | $429 | $27 |
2022: 2 drugs
| Azelastine | 22 | $855 | $39 |
| Fluticasone Propionate | 17 | $381 | $22 |
2021: 1 drug
| Azelastine | 15 | $355 | $24 |
2017: 6 drugs
| Atorvastatin | 15 | $328 | $22 |
| Hydrochlorothiazide | 17 | $105 | $6 |
| Simvastatin | 11 | $90 | $8 |
| Paroxetine | 12 | $85 | $7 |
| Lisinopril | 12 | $80 | $7 |
| Metformin | 14 | $76 | $5 |
2016: 9 drugs
| Atorvastatin | 29 | $587 | $20 |
| Valsartan | 12 | $450 | $38 |
| Levothyroxine | 11 | $137 | $12 |
| Simvastatin | 21 | $122 | $6 |
| Paroxetine | 24 | $98 | $4 |
| Tramadol | 20 | $96 | $5 |
| Omeprazole | 15 | $77 | $5 |
| Hydrochlorothiazide | 16 | $63 | $4 |
| Metformin | 11 | $51 | $5 |
Money from drug and device companies
$35 in 2019
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | None | $35 | 1 payment
|
See the published payment
| Novartis Pharmaceuticals | Meals · 2019-11-09 | None | $35 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1063839264
- Licence
- CA A161744California A161744: Current · expires 2027-04-30
- Group
- Stanford Health Care · Lpch Medical Group Div of Lucile
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0201X (207RA0201X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-03-25
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.